Hostname: page-component-7c8c6479df-xxrs7 Total loading time: 0 Render date: 2024-03-29T02:47:30.374Z Has data issue: false hasContentIssue false

Personality disorders and depression

Published online by Cambridge University Press:  26 September 2002

M. FAVA
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
A. H. FARABAUGH
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
A. H. SICKINGER
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
E. WRIGHT
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
J. E. ALPERT
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
S. SONAWALLA
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
A. A. NIERENBERG
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
J. J. WORTHINGTON III
Affiliation:
From the Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Abstract

Background. Personality disorders (PDs) were assessed among depressed out-patients by clinical interview before and after antidepressant treatment with fluoxetine to assess the degree of stability of PD diagnoses and determine whether changes in PD diagnoses across treatment are related to the degree of improvement in depressive symptoms.

Method. Three hundred and eighty-four out-patients (55% women; mean age = 39.9±10.5) with major depressive disorder (MDD) diagnosed with the SCID-P were enrolled into an 8 week trial of open treatment with fluoxetine 20 mg/day. The SCID-II was administered to diagnose PDs at baseline and endpoint.

Results. A significant proportion (64%) of our depressed out-patients met criteria for at least one co-morbid personality disorder. Following 8 weeks of fluoxetine treatment, there was a significant reduction in the proportion of patients meeting criteria for avoidant, dependent, passive-aggressive, paranoid and narcissistic PDs. From baseline to endpoint, there was also a significant reduction in the mean number of criteria met for paranoid, schizotypal, narcissistic, borderline, avoidant, dependent, obsessive–compulsive, passive aggressive and self-defeating personality disorders. While changes in cluster diagnoses were not significantly related to improvement in depressive symptoms, there were significant relationships between degree of reduction in depressive symptoms (percentage change in HAM-D-17 scores) and degree of change in the number of criteria met for paranoid, narcissistic, borderline and dependent personality disorders.

Conclusions. Personality disorder diagnoses were found to be common among untreated out-patients with major depressive disorder. A significant proportion of these patients no longer met criteria for personality disorders following antidepressant treatment, and changes in personality disorder traits were significantly related to degree of improvement in depressive symptoms in some but not all personality disorders. These findings suggest that the lack of stability of PD diagnoses among patients with current MDD may be attributable in part to a direct effect of antidepressant treatment on behaviours and attitudes that comprise PDs.

Type
Research Article
Copyright
© 2002 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)